Happi Staff12.31.20
Wellness BioSciences Rx, Houston, TX, has been sent a warning letter by the FDA following a review of its website in September 2020 and December 2020 where it sells products containing cannabidiol (CBD). The agencies also cited posts made on social media channels.
The products included an inhaler, soft gels and drops as well as WBRx Relief Balm CBD, a topical product.
According to FDA, the claims on the website and social media website establish that the firm’s CBD products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs sold in violation of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1).
The products included an inhaler, soft gels and drops as well as WBRx Relief Balm CBD, a topical product.
According to FDA, the claims on the website and social media website establish that the firm’s CBD products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs sold in violation of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1).
